Señales en vivo de ME | Maximiza tus Ganancias con Getagraph.com

COMPRAR 111042 min ago

@ $0.773

Emitido: 14 feb 2024 @ 15:29

Retorno: -35.26%

Señal anterior: feb 14 - 10:21

Señal anterior: Vender

Retorno: 3.62 %

Live Chart Being Loaded With Signals

Commentary (1 may 2024 @ 16:00):

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics...

Stats
Volumen de hoy	3.08M
Volumen promedio	7.56M
Capitalización de mercado	241.60M
EPS	$0 ( 2024-02-07 )
Próxima fecha de ganancias	( $-0.150 ) 2024-05-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.450
ATR14	$0.00100 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Hibbs Kathy L	Buy	38 548	Class A Common Stock
2024-04-18	Hibbs Kathy L	Sell	38 548	Class A Common Stock
2024-04-18	Hibbs Kathy L	Sell	38 548	Stock Option (Right to Buy)
2024-04-04	Hibbs Kathy L	Buy	38 548	Class A Common Stock
2024-04-04	Hibbs Kathy L	Sell	38 548	Class A Common Stock

INSIDER POWER
73.76
Last 100 transactions
Buy: 15 283 999 \| Sell: 2 077 892

Volumen Correlación

Largo: -0.06 (neutral)

Corto: -0.98 (very strong negative)

Signal:(35.976) Neutral

23andMe Holding Co. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

23andMe Holding Co. Correlación - Moneda/Commodity

0.04
( neutral )

-0.68
( moderate negative )

0.00
( neutral )

0.59
( weak )

23andMe Holding Co. Finanzas

Annual	2022
Ingresos:	$299.49M
Beneficio Bruto:	$134.50M (44.91 %)
EPS:	$-0.690

FY	2022
Ingresos:	$299.49M
Beneficio Bruto:	$134.50M (44.91 %)
EPS:	$-0.690

FY	2022
Ingresos:	$271.89M
Beneficio Bruto:	$132.95M (48.90 %)
EPS:	$-0.600

FY	2021
Ingresos:	$243.92M
Beneficio Bruto:	$117.01M (47.97 %)
EPS:	$-0.398

Financial Reports:

No articles found.

23andMe Holding Co.

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.